Built by a team that has published hundreds of peer-reviewed studies with tens of thousands of citations across addiction science, digital intervention, and cannabis research.
Awarded through the Small Business Innovation Research program at the National Institute on Drug Abuse, the gold standard for behavioral health research funding in the United States. Most applicants never clear Phase I.
✓
Phase I
Feasibility
Proved the program could work as a standalone digital intervention.
✓
Phase II
Efficacy at scale
Funding the full trial and build of the therapeutic.
SBIR · NIDA
Competitive, peer-reviewed federal grant program
✓
Phase I
Complete
A 30-day cannabis break built for people under 21
Funded the design, build, and pilot of a version of Clear30 for young adults, and established that they will use it.
2
Phase II
Awarded
The first standalone digital therapeutic for cannabis use disorder
Funds the clinical trial and the FDA regulatory pathway toward a prescribable treatment for cannabis use disorder.
3
What comes next
Ahead
FDA clearance as a prescribable treatment
The goal is the first cleared digital therapeutic for cannabis use disorder, prescribable like any other treatment.
Our research partner
MGH / Harvard Medical School
We work with the Recovery Research Institute at Massachusetts General Hospital and Harvard Medical School, so the people measuring whether Clear30 works are not the people who built it.
Results on use, mood, and retention across the first campus cohorts, run by the Recovery Research Institute.
Scientific and clinical advisors
Advisory leadership
Expert guidance across addiction science, clinical care, public health policy, and behavior change, so Clear30 is developed and evaluated the way institutions expect.
Our founder
Fred Muench, PhD
Co-Founder & Chief Science Officer
Two decades of published work on digital behavior change and addiction care, including the largest mobile addiction study ever run.
Clear30 for Universities